UNSPSC 51343602: Methisazone or metisazone

This classification denotes an antiviral agent with the molecular formula C10H10N4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3QML4J07E, chemically known as 1-methylindole-2,3-dione 3-(thiosemicarbazone) but generally known as methisazone, which bears US NIH Compound Identifier 6861563. European Medicines Agency schedules Metisazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08895MIG. The term METHISAZONE is an International Non-Proprietary Name.

World Health Organization schedules methisazone in its Anatomical Therapeutic Chemical (ATC) Classification. Methisazone or metisazone bears US NLM identifiers UMLS ID C0025656 and NCI Concept Code C77928. SMILES: CN1C2=CC=CC=C2C(=NNC(=S)N)C1=O.

UNSPSC 51343602 Methisazone or metisazone is a Commodity code that nominally covers antiviral pharmaceutical compounds, though recent state and local procurement activity under this code shows little alignment with the code's stated scope. The most recent opportunities posted under the code involve naloxone (an opioid antagonist) and safe drug deactivation systems, neither of which falls within methisazone's pharmaceutical category. State and local procurement offices appear to be using this code inconsistently or as a catch-all for emergency pharmaceutical and medical supply acquisitions rather than for the specific antiviral compound the code names.

The two most recent opportunities reflect fragmented issuing bodies and geographically dispersed activity. The Illinois Department of Public Health posted a completed award (not an open solicitation) on August 28, 2026, for a piggyback pharmaceutical warehouse order through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC, though that contract covered doxycycline hyclate and ciprofloxacin hydrochloride, not methisazone. Seminole County, Florida issued an IFB on June 30, 2026, with a response deadline of July 26, 2023, seeking annual procurement of naloxone and drug deactivation systems through competitive bidding. The code shows limited, scattered recent activity with significant scope misalignment—vendors pursuing opportunities tagged under UNSPSC 51343602 should verify actual commodity requirements in RFP and IFB documents rather than relying on the code classification alone.